High density lipoprotein future or investigational therapies: Difference between revisions
Rim Halaby (talk | contribs) No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
There are promising future therapies that include CETP inhibitors, which are currently in the experimental phase. A combination therapy with [[statins]] and [[ACE inhibitors]] is also a safe option in patients with [[HDL]] levels who also share features with [[dysmetabolic syndrome]]. However, the preventive effects of these two drugs tend to be cumulative.<ref name="pmid12821213">{{cite journal |author=Liem AH, Jukema JW, van Veldhuisen DJ |title=Secondary prevention in coronary heart disease patients with low HDL: which options do we have? |journal=[[International Journal of Cardiology]] |volume=90 |issue=1 |pages=15–21 |year=2003 |month=July |pmid=12821213 |doi= |url=}}</ref> | There are promising future therapies that include CETP inhibitors, which are currently in the experimental phase. A combination therapy with [[statins]] and [[ACE inhibitors]] is also a safe option in patients with [[HDL]] levels who also share features with [[dysmetabolic syndrome]]. However, the preventive effects of these two drugs tend to be cumulative.<ref name="pmid12821213">{{cite journal |author=Liem AH, Jukema JW, van Veldhuisen DJ |title=Secondary prevention in coronary heart disease patients with low HDL: which options do we have? |journal=[[International Journal of Cardiology]] |volume=90 |issue=1 |pages=15–21 |year=2003 |month=July |pmid=12821213 |doi= |url=}}</ref> | ||
==HDL | ==Infusion of Reconstituted HDL== | ||
===ApoA-1 Milano=== | |||
===CSL-112=== | |||
===CER-001=== | |||
==Cholesterol Ester Transfer Protein (CETP) Inhibition== | |||
===Torcetrapib=== | |||
===Dalcetrapib=== | |||
===Anacetrapib=== | |||
===Evacetrapib=== | |||
==Other Therapies== | |||
===Endocannabinoid receptor blockers=== | |||
===JTT-705=== | |||
===CETi-1 Vaccine=== | |||
Revision as of 12:28, 19 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
High density lipoprotein future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of High density lipoprotein future or investigational therapies |
|
FDA on High density lipoprotein future or investigational therapies |
|
CDC on High density lipoprotein future or investigational therapies |
|
High density lipoprotein future or investigational therapies in the news |
|
Blogs on High density lipoprotein future or investigational therapies |
|
Risk calculators and risk factors for High density lipoprotein future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Overview
There are promising future therapies that include CETP inhibitors, which are currently in the experimental phase. A combination therapy with statins and ACE inhibitors is also a safe option in patients with HDL levels who also share features with dysmetabolic syndrome. However, the preventive effects of these two drugs tend to be cumulative.[1]
Infusion of Reconstituted HDL
ApoA-1 Milano
CSL-112
CER-001
Cholesterol Ester Transfer Protein (CETP) Inhibition
Torcetrapib
Dalcetrapib
Anacetrapib
Evacetrapib
Other Therapies
Endocannabinoid receptor blockers
JTT-705
CETi-1 Vaccine
References
- ↑ Liem AH, Jukema JW, van Veldhuisen DJ (2003). "Secondary prevention in coronary heart disease patients with low HDL: which options do we have?". International Journal of Cardiology. 90 (1): 15–21. PMID 12821213. Unknown parameter
|month=ignored (help)